Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials.

MLA

Kauer, Joseph, et al. “Stem Cell Collection after Lenalidomide, Bortezomib and Dexamethasone plus Elotuzumab or Isatuximab in Newly Diagnosed Multiple Myeloma Patients: A Single Centre Experience from the GMMG-HD6 and -HD7 Trials.” BMC Cancer, vol. 23, no. 1, Nov. 2023, p. 1132. EBSCOhost, https://doi.org/10.1186/s12885-023-11507-9.

APA

Kauer, J., Freundt, E. P., Schmitt, A., Weinhold, N., Mai, E. K., Müller-Tidow, C., Goldschmidt, H., Raab, M. S., Kriegsmann, K., & Sauer, S. (2023). Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. BMC Cancer, 23(1), 1132. https://doi.org/10.1186/s12885-023-11507-9

Chicago

Kauer, Joseph, Emma P Freundt, Anita Schmitt, Niels Weinhold, Elias K Mai, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc S Raab, Katharina Kriegsmann, and Sandra Sauer. 2023. “Stem Cell Collection after Lenalidomide, Bortezomib and Dexamethasone plus Elotuzumab or Isatuximab in Newly Diagnosed Multiple Myeloma Patients: A Single Centre Experience from the GMMG-HD6 and -HD7 Trials.” BMC Cancer 23 (1): 1132. doi:10.1186/s12885-023-11507-9.